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Abstract
Background: In cost-effectiveness analyses in healthcare, Quality-Adjusted Life Years are often used as outcome measure of 
effectiveness. However, there is an ongoing debate concerning the appropriateness of its use for decision-making in palliative care.
Aim: To systematically map pros and cons of using the Quality-Adjusted Life Year to inform decisions on resource allocation among 
palliative care interventions, as brought forward in the debate, and to discuss the Quality-Adjusted Life Year’s value for palliative care.
Design: The integrative review method of Whittemore and Knafl was followed. Theoretical arguments and empirical findings were 
mapped.
Data sources: A literature search was conducted in PubMed, EMBASE, and CINAHL, in which MeSH (Medical Subject Headings) 
terms were Palliative Care, Cost-Benefit Analysis, Quality of Life, and Quality-Adjusted Life Years.
Findings: Three themes regarding the pros and cons were identified: (1) restrictions in life years gained, (2) conceptualization of quality 
of life and its measurement, including suggestions to adapt this, and (3) valuation and additivity of time, referring to changing valuation of 
time. The debate is recognized in empirical studies, but alternatives not yet applied.
Conclusion: The Quality-Adjusted Life Year might be more valuable for palliative care if specific issues are taken into account. 
Despite restrictions in life years gained, Quality-Adjusted Life Years can be achieved in palliative care. However, in measuring quality of 
life, we recommend to—in addition to the EQ-5D— make use of quality of life or capability instruments specifically for palliative care. 
Also, we suggest exploring the possibility of integrating valuation of time in a non-linear way in the Quality-Adjusted Life Year.
Keywords
Quality-Adjusted Life Year, debate, cost-effectiveness analysis, palliative care
1 IQ healthcare, Radboud Institute for Health Sciences, Radboud 
University Medical Center, Nijmegen, The Netherlands
2 Department for Health Evidence, Radboud University Medical Center, 
Nijmegen, The Netherlands
3 End-of-life Care Research Group, Vrije Universiteit Brussel (VUB) and 
Ghent University, Brussels, Belgium
4 Department of Anesthesiology, Pain and Palliative Care, Radboud 
University Medical Center, Nijmegen, The Netherlands
†PACE: Palliative Care in Care Homes Across Europe. An EU-funded 
international research project
Corresponding author:
Anne B Wichmann, IQ healthcare, Radboud Institute for Health 
Sciences, Radboud University Medical Center, P.O. Box 9101, 6500 HB 
Nijmegen, The Netherlands. 
Email: Anne.Wichmann@radboudumc.nl
689652 PMJ0010.1177/0269216316689652Palliative MedicineWichmann et al.
review-article2017
Review Article
What is already known about the topic?
•• Medical (technological) progress and resulting competing alternatives increasingly raise the question “must everything that 
can be done, be done?” The Quality-Adjusted Life Year (QALY) is widely used as outcome measure for cost-effectiveness 
analyses in healthcare. However, there is an ongoing debate concerning the appropriateness of its use to inform decisions 
on resource allocation among palliative care interventions.
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Background
Patients are entitled to receive timely, acceptable, and 
affordable care of appropriate quality.1 Due to new 
(expensive) drugs and treatments, and the fact that people 
live longer, the duration of intensive and costly care has 
increased. This puts pressure on the collective affordabil-
ity of our healthcare. The question “must everything that 
can be done, be done?” is being asked more frequently, 
particularly in end-of-life care (EoLC). Palliative care 
also competes for limited healthcare resources. Since the 
number of patients in advanced stages of incurable condi-
tions is increasing,2,3 expenditures in this field are likely 
to increasingly represent a bigger share of total spending.
Because of this, economic evaluations used when allo-
cating resources are becoming increasingly important.4 
Insight into the effectiveness, its costs, and their incremen-
tal ratio (incremental cost-effectiveness) is important when 
allocating resources. It is frequently argued that the evalua-
tion of palliative care interventions should also include 
cost-effectiveness.5–8 The Quality-Adjusted Life Year 
(QALY) is the predominant outcome measure for cost-
effectiveness analyses (CEAs) in healthcare, and its use is 
recommended by both the National Institute for Health and 
Clinical Excellence (NICE) and the Dutch guideline for 
economic evaluation in healthcare.9–11 However, in the (sci-
entific) palliative care community, a debate concerning the 
appropriateness of the QALY’s use as part of the efficiency 
decision rule in palliative care is taking place.6,7,12–14
The QALY takes into account two factors: the quality 
(of life; “Q”) and the quantity (life years gained; “LY”) 
generated by healthcare interventions. In the QALY, the 
length of time spent in a certain health state is weighed by 
the utility score given to that health state.15 For instance, 1 
year of perfect health is worth one QALY, a year of less 
than perfect health is worth less than one QALY, and death 
is considered to be equivalent to zero QALYs. Some health 
states may be considered worse than death and 
have negative scores.15 By integrating Q and LY, the QALY 
provides a common metric to measure the added values 
from a variety of interventions, making it useful for 
budget allocation. In principle, deciding to allocate 
resources toward a specific intervention depends on the 
value for money question in terms of societal willingness 
to pay for a QALY gained.
This general application of the QALY, however, also 
contains a major objection.16 Some think that the nature 
of palliative care makes it more difficult to provide evi-
dence on efficiency, which puts palliative care in a disad-
vantaged position when competing for resources with 
other healthcare services that have better evidence.17–19 It 
is argued that other approaches, such as the capability 
approach, in which capabilities are considered rather than 
functioning,14 might provide a richer evaluative space. 
The aim of this review is to systematically map pros and 
cons of using the QALY to inform decisions on resource 
allocation among palliative care interventions as brought 
forward in the debate and to discuss the QALY’s value 
for palliative care.
Methods
Rationale
In order to unfold the coherent body of knowledge, insights 
generated from separate studies were integrated using 
Whittemore and Knafl’s20 methodology for integrative 
reviews. Both non-empirical (theoretical) and empirical 
(CEAs) literature was searched. Theoretical literature was 
analyzed from bottom-up to find and compare arguments 
regarding the appropriateness of using the QALY to inform 
decisions on resource allocation among palliative care 
interventions. All the pro- and con arguments were pre-
sented in their original form regardless of their strength. In 
What this paper adds?
•• This paper offers the first systematic overview of pros and cons of using QALYs to inform decisions on resource alloca-
tion among palliative care interventions. It provides a critical appraisal of the arguments and discusses the QALYs’ value 
for palliative care. Furthermore, it explores whether difficulties are experienced in research practice and how they are 
dealt with, for example, are alternative approaches or outcome measures used?
Implications for practice, theory, or policy
•• Our review concludes that, despite criticisms, the QALY might be of value in informing decisions on resource allocation 
among palliative care interventions if specific issues are taken into account. Since standard quality-of-life measurement 
instruments (such as the EQ-5D) lack dimensions that are essential to palliative care, we recommend to add quality-of-
life or capability instruments for economic evaluations in palliative care. Also, we suggest exploring the possibility of 
integrating valuation of time in a non-linear way in the QALY framework. However, to appropriately allocate scarce 
resources across healthcare, a common metric is needed. Therefore, the issues suggested should not remain restricted 
to palliative care, but be considered in the QALY conceptualization throughout healthcare.
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the discussion, the various arguments were critically 
appraised and the value of QALYs for palliative care was 
discussed. Analysis of the CEAs focused on identifying 
whether the perceived difficulties are described in research 
practice.
Literature search and data extraction
A literature search was conducted in the electronic data-
bases PubMed, EMBASE, and CINAHL (Table 1). MeSH 
(Medical Subject Headings) terms in the search strategy 
were Palliative Care, Cost-Benefit Analysis, Quality of 
Life, and Quality-Adjusted Life Years. The search was lim-
ited to English-language articles published between 2000 
and May 2015. In March 2016, a search update was done. 
Reference lists were scanned iteratively for supplementary 
publications.
In assessing the records identified by the database 
search, the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) flowchart was 
used (Figure 1).21 After identification of the records and 
the removal of duplications, titles and abstracts were 
screened for their relevance. If the article did not concern 
our research question, for example, when the title or 
abstract not indicated the study concerned cost-effective-
ness/utility analysis within the palliative care field, it was 
excluded. Then, full-text articles were read to evaluate 
their eligibility. Inclusion and exclusion (Tables 2 and 3) in 
both the screening and the eligibility rounds were indepen-
dently done by two researchers (A.B.W. and S.K.). Since 
the emphasis was on finding various pros and cons of 
using the QALY in palliative care, an inclusive sampling 
approach was used. That is, all titles that seemed to be of 
interest were included. Primary sources were not assessed 
on their individual quality.
Data analysis
In order to provide a comprehensive understanding of pros 
and cons of using QALYs to inform decisions on resource 
allocation among palliative care interventions, the sto-
ryline of the coherent body of knowledge was unfolded. 
Heterogeneous literature (Tables 4 and 5 in Appendix 1) 
was explored and analyzed. The research strategy for inte-
grative reviews was used for data analysis.20 Two sub-
groups consisting of theoretical and empirical literature 
were analyzed separately (see the following subsections). 
Subsequently, the theoretical and empirical subgroups 
were integrated.23
Theoretical literature. Pros and cons of using the QALY in 
palliative care, as well as alternative outcome measures and 
approaches, were inferred from the theoretical literature. 
All arguments from primary sources were coded, ordered, 
and clustered to identify patterns that could be translated 
into themes (Table 6 in Appendix 1). To meaningfully ana-
lyze the arguments, it was done in chronological order.
Empirical literature. Empirical CEAs were studied to find 
out whether perceived difficulties are experienced in 
research practice in the theoretical literature and how they 
are being dealt with, for example, are alternative 
approaches or outcome measures used? A data extraction 
form was used to systematize all findings. The empirical 
studies were ordered alphabetically, by author name, and 
on methodological characteristics (Table 5 in Appendix 1).
Table 1. Electronic databases for search strategies.
PubMed EMBASE CINAHL
(((((((Quality Adjusted Life Year[tiab] 
OR Quality Adjusted Life Years[tiab] 
OR QALY[tiab] OR QALYs[tiab]))) OR 
“Quality-Adjusted Life Years”[Mesh])) 
OR (((((“Quality of Life”[Mesh]) OR 
quality of life[tiab]) OR life quality[tiab])) 
AND (((“Cost-Benefit Analysis”[Mesh]) 
OR ((Cost Benefit[tiab] OR Cost 
Effectiveness[tiab] OR Cost Utility[tiab] 
OR Costs and Benefits[tiab] OR Benefits 
and Costs[tiab]))))))) AND (((((“Hospice 
Care”[Mesh]) OR “Terminal 
Care”[Mesh:noexp])) OR “Palliative 
Care”[Mesh]) OR ((Palliative[tiab] 
OR Terminal care[tiab] OR End of life 
care[tiab] OR EOLC[tiab] OR EOL 
care[tiab] OR hospice care[tiab] OR 
Hospice Programs[tiab] OR Hospice 
Program[tiab])))
(terminal care/or hospice care/
OR palliative therapy/OR 
(Palliative or Terminal care or 
End of life care or EOLC or EOL 
care or hospice care or Hospice 
Programs or Hospice Program).
ti,ab.) AND ((Cost Benefit or 
Cost Effectiveness or Cost 
Utility or (Costs and Benefits) 
or (Benefits and Costs)).ti,ab. 
OR cost benefit analysis/or cost 
effectiveness analysis/) AND (exp 
“quality of life”/OR (quality of life 
or life quality).ti,ab OR (Quality 
Adjusted Life Year or Quality 
Adjusted Life Years or QALY or 
QALYs).ti,ab. OR quality adjusted 
life year/)
((MH “Hospice Care”) OR (MH “Palliative Care”) 
OR (MH “Terminal Care”) OR (TI Palliative OR 
Terminal care OR End of life care OR EOLC OR 
EOL care OR hospice care OR Hospice Programs 
OR Hospice Program) OR (AB Palliative OR 
Terminal care OR End of life care OR EOLC 
OR EOL care OR hospice care OR Hospice 
Programs OR Hospice Program)) AND ((MH 
“Cost Benefit Analysis”) OR (TI Cost Benefit OR 
Cost Effectiveness OR Cost Utility or (Costs and 
Benefits) or (Benefits and Costs)) OR (AB Cost 
Benefit OR Cost Effectiveness OR Cost Utility 
or (Costs and Benefits) or (Benefits and Costs))) 
AND ((MH “Quality of Life”) OR (MH “Comfort”) 
OR (TI quality of life OR life quality) OR (AB 
quality of life OR life quality) OR (MH “Quality-
Adjusted Life Years”) OR (TI Quality Adjusted Life 
Year or Quality Adjusted Life Years or QALY or 
QALYs) OR (AB Quality Adjusted Life Year or 
Quality Adjusted Life Years or QALY or QALYs))
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Findings
Of the 993 publications initially identified through data-
base searching and snowballing, 753 studies of potential 
interest were left after removal of duplications (Figure 1). 
A total of 13 theoretical and 30 empirical CEAs were 
included. The theoretical literature encompassed clinical, 
economic, policy/management, and philosophical studies. 
Tables 4 and 5 in Appendix 1 show the characteristics of 
the included studies.
Interpretation and integration
After ordering all arguments regarding the use of the QALY 
to inform decisions on resource allocation among palliative 
care interventions—as they were originally brought for-
ward in the literature—three themes were identified from 
bottom-up (Table 6 in Appendix 1). These themes concern 
groups of arguments about the “life years gained,” “con-
ceptualization of quality of life (QoL) and its measure-
ment,” and the “valuation and additivity of time” elements 
of the QALY. Some of these arguments could also be found 
in the empirical literature (Table 7 in Appendix 1), and 
some were supported by alternative outcome measures or 
approaches such as the “PalY” and the “Peak End Rule.” In 
the discussion, we critically appraise the main arguments 
and the value of QALYs for palliative care.
Theme 1. Life years gained
Low life expectancy is considered to be a problem (con). Some 
authors view the LY component of the QALY as problem-
atic. It is argued that the main objective of palliative care is 
to improve QoL and enable people to opt for a dignified 
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram.22
Table 2. Inclusion and exclusion criteria of theoretical papers.
Inclusion Exclusion
Years 2000–2016 Reviews
Non-empirical papers (articles, 
editorial letters, etc.)
Non-English language 
studies
Studies about pros or cons of using 
QALYs in palliative care
 
Studies about quantifying quality of 
EoLC
 
QALY: Quality-Adjusted Life Year; EoLC: end-of-life care.
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death14 and not (necessarily) prolonging survival.5,14,18 
Egan,5 for example, argues that the QALY has the implicit 
and flawed assumption that interventions should prolong 
survival to be valuable. He states that since patients eligi-
ble for palliative care have a relatively low life expectancy, 
any life-saving therapy will result in potentially higher 
QALY gains.5 A consequence of this assumption, it is 
posed, is that even when costs are quite modest, palliative 
care interventions cannot prove themselves to be cost-
effective, as there is no enough time for them to generate 
QALYs.5,12 This difficulty is also encountered in empirical 
studies.24,25,26 For instance, Stevenson et al.24 state that 
“any survival advantage has a marked effect on the cost-
effectiveness, which reflects the frequent issue that it can 
be more cost-effective to let patients die rather than to use 
relatively costly treatments.”
Gains in QALYs are possible even if life expectancy is low 
(pro). Hughes6 contends against this argument by citing 
Keynes’ “in the long run we are all dead.” This fact, he 
argues, does not make QALY analysis inapplicable across 
the board. After all, our QoL matters while we are alive, 
and this is what the QALY seeks to capture, too.6 This view 
is supported by Round,7 who by means of an illustration 
shows that increases in QALYs are possible even if life 
cannot be lengthened. This is also backed by empirical 
studies that found that their results were most sensitive to 
changes in utilities,27 and that palliative therapies began to 
gain very high QALY values with only modest decreases 
in QoL.28 This implies that the Q weight significantly 
influences the QALY, and that survival advantage even 
seems to be undermined by declines in QoL. Moreover, 
Hughes6 poses the objective of improving QoL (or limit its 
potential loss, red.) rather than increasing life expectancy 
is true for other non-life prolonging interventions which 
can be measured in QALYs, such as hip operations. In 
other words, gains in QALYs are possible even if one of its 
components does not change significantly, since improve-
ments can be made in the other component.7
Theme 2. Conceptualization of QoL and its 
measurement
Health-related domains are less relevant in palliative care 
(con). Other arguments concern the Q weight of the 
QALY. One of the main arguments is about its conceptu-
alization and measurement. The instrument predomi-
nantly used to measure the Q weight is the EuroQol 
instrument (EQ-5D). However, the health-related QoL 
(HR-QoL) dimensions—pain/discomfort, anxiety/
depression, mobility, self care, and usual activities—that 
are covered by this instrument are often seen as less rel-
evant in the context of palliative care, in which values 
such as patient dignity, spiritual and psychosocial well-
being, and bereavement support are central. These rather 
broad, multidimensional, complex, and holistic inten-
tions of palliative care are said to be lacking in HR-QoL 
measurement instruments such as the EQ-5D.12,29 In other 
words, the authors argue that the EQ-5D is mainly con-
cerned with health and the recovery of health, and not 
with the quality of end of life (EoL) or dying.
Do not dismiss the framework: develop valid measurement 
instruments (pro). Yang and Mahon,30 however, argue that 
palliative care and the QALY are compatible. They state 
that “like QALY and cost-utility calculations, palliative 
care involves a benefit-burden analysis for optimal treat-
ment recommendations.” However, they argue that pallia-
tive care must be optimally integrated in QALY 
calculations.8 Other authors are also convinced that, 
despite current difficulties, the champagne should not be 
thrown out with the cork. Improper measurement (as of 
Table 3. Inclusion and exclusion criteria of empirical (CE) papers.
Inclusion Exclusion
Years 2000–2016 Reviews
Journal articles Non-English language studies
Cost-effectiveness/utility studies Conference abstracts
Studies in advanced, mortally ill patients (EOL period during which a 
person’s condition is actively deteriorating and when death is expected)
Study protocols
Studies written from palliative care paradigm BSC studies
 Studies in non-human or children
 Broader palliative care studies
 Broader health economic studies (without CE analyses)
 Chronic/allergic/non-EOL diseases
 First-line/primary treatments
 Critical/intensive care studies
 Studies about predictive testing/prevention/screening
 Studies on developing/evaluating new interventions
CE: cost-effectiveness; EOL: end of life; BSC: best supportive care.
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yet) of the Q weight of the QALY should not result in a 
relinquishment of the whole outcome measure.6,7,31 
Hughes6 argues, what should be done is develop the best 
ways for estimating QoL. According to Chochinov,29 in 
palliative care, this means measurement should embrace a 
perspective as broad as the notion of QoL itself. With fur-
ther refinements of analytical instruments, the conviction 
is that palliative care can be optimally integrated in the 
QALY calculation.30 Coast,14 with the capability approach, 
argues for a richer evaluative space when measuring QoL.
… this flexibility is offered in the extra-welfarist framework 
(pro). Round7 agrees that instruments could be developed 
that take account of the domains of relevance to a certain 
population. This flexibility of preference-based measure-
ment is said to be offered within the extra-welfarism 
framework. In this (conceptual) approach, non-health 
domains next to or instead of health-related domains, or 
capabilities instead of functioning,14 can or should prefer-
ably be considered when estimating QALYs. It is argued 
that accepting some degree of heterogeneity in QoL meas-
urement may be less detrimental than squeezing all evalu-
ation activity into standard instruments.18 This flexibility, 
however, is said to be rarely applied in research practice,7 
and “the fact that researchers have not taken advantage of 
this flexibility is not a criticism of the framework itself.”7
An extra-welfarist capability approach (con). Coast and col-
leagues,14,32 inspired by the work of Amartya Sen,33–35 make 
the case for the capability approach. In this approach, inter-
ventions are not based solely on functioning but are assessed 
based on their impact on what a person is able to do or be—
in terms of capabilities that allow a person to have a good 
EoL.14 Although there is disagreement on the scope to which 
these capabilities can differ,36,37 Coast14 advocates for differ-
ent sets of capabilities in different contexts.
The Palliative Care Yardstick as alternative approach (con). An 
alternative approach also using this flexibility is suggested 
by Normands’12 Palliative Care Yardstick (PalY). By add-
ing items to the QALY, the PalY would incorporate dimen-
sions of palliative care (i.e. caring externalities) that are 
not considered when calculating QALYs.12 This approach, 
however, has not yet been studied in practice.
(Availability of) instruments not known (con). In the empirical 
literature, mostly (standard) HR-QoL measurement instru-
ments—such as the EQ-5D, EORTC QLQ-LC13/30, and 
SF-36—were used (Table 5 in Appendix 1). In one of these 
CEAs, it is noted that standard HR-QoL instruments were 
used that do not include QoL domains specifically relevant 
for the valuation of EoLC, due to the assumption that 
“unfortunately, no valuation instrument exists that incorpo-
rates such issues.”38 In the empirical literature, some 
authors look for intermediate solutions for this problem by 
taking into account aspects of HR-QoL that have the largest 
impact on general QoL in palliative patients. Barton et al.39 
for example, use response to pain treatment in their utility 
calculations, since “chronic pain has an enormous effect on 
QoL of patients with bone metastases.” Pace et al.40 meas-
ure rehospitalization, as this is correlated with a lack of 
symptom control, worsening patient QoL.
Linear continuum and the narrative approach (con). Another 
main argument against the use of the QALY in palliative 
care is its assumption of a mathematical linear continuum 
between death (0) and excellent health (1).5,12 Authors spe-
cifically have a problem with the fixed valuing of zero for 
death, due to which the benefits of a good or desired death 
currently cannot be captured.12,41 Normand12 argues that 
the non-linearity could be “accepted” by putting a value on 
components of a good death, and that this non-linear valu-
ing would be separate from the days that led up to it (We 
will come back to the valuation question in theme 3.). The 
linear continuum assumption is challenged by the narra-
tive approach.6 This theory describes that the manner in 
which a life ends impacts the overall value of that life. In 
this approach, the benefit of good EoLC is independent of 
any particular time-slice and thus cannot be captured by 
the QALY.6 Hughes6 and Cowley42 are in favor of this 
approach, as good terminal care adds greater meaning to 
the past life, and “the increase in rediscovered meaningful 
years can be measured backwards rather than forwards.” 
Cowley argues that this increase in rediscovered life years 
can even constitute new quality life years, since quality is 
retrospectively added to lived years.
Theme 3. Valuation and additivity of time
Valuation of time increases as time is running out (con). As 
briefly mentioned above, the QALY assumes that prefer-
ences on time are stable. Therefore, in the QALY methodol-
ogy, it is common practice to weight each year of added life 
equally. That is, time for any individual at any point in time 
is treated as being constant, making it additive.18 By some, 
this feature of additivity is seen as problematic,5,12 since 
valuation of time might not be fixed.12,29,43 It would increase 
as time itself runs out.29,41 Chochinov29 describes it as fol-
lows: “Each moment becomes increasingly precious as 
death draws near, while for the rest of the world, the clock 
marks time at its usual pace, with its usual indifference.”
Adding the Valuation Index Palliative to the PalY (con). Nor-
mands’ previously introduced PalY not only suggests add-
ing items to the QALY, but also deals with the valuation 
problem. For example by allowing a value to be put on 
components of a “good death,” which is separate from the 
days that led up to it. Chochinov further explores the PalY 
suggestion by adding the Valuation Index Palliative (VIP). 
In the VIP, the supposed increasing value of time as death 
gets closer is taken into account by ascribing a higher 
value to time in proximity to death.29 Although these 
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concepts did not (yet) reach research practice, Furlan et al., 
in their empirical study, theorize about this idea:
… patients at the EoL tend to have low QALYs because of 
very poor health status […] This raises the question of whether 
economic evaluations […] ought to use some adjustment that 
would give additional weight to gains to health occurring at 
the EoL.
Billingham et al.44 may have used the VIP. They state 
that their CEA takes no account of the diminishing mar-
ginal utility, but that “an extra 2 months of good QoL to a 
life-expectancy of 6 months is potentially more valuable 
than an extra 2 months to a much better average 
life-expectancy.”
And: the willingness to pay for it increases (con). When follow-
ing this line of reasoning, a QALY gained at the EoL would 
not be equivalent to a QALY gained earlier in life.41 Moreo-
ver, a rising willingness to pay for time gained at the EoL is 
assumed.29 This line of reasoning can also be found in 
empirical studies. Arguedas et al.45 state that in their CEA, 
“a value closer to $100,000 per QALY [instead of the regu-
larly cited threshold of $50,00046] might more accurately 
reflect societal preferences.” Furlan et al.47 argue that their 
results “indicate that increased expenditures are needed to 
impact patients’ QoL for such morbid clinical conditions.” 
According to Haycox,41 society indeed appears to show a 
willingness to pay for palliative care that lies above the 
level that would be considered “rational.”
Or doesn’t it? (pro). Hughes6 though, objects to this reason-
ing since, according to him, it is not clear that palliative 
patients have greater needs than others. So, it cannot be the 
sole criterion for distribution of resources. He poses it 
should be combined with some measure of benefit.6 
Round7 agrees that equity issues arise when resource allo-
cation decisions are made based on situations that are no 
more unique to patients at the EoL than they are at any 
other life stages. Round43 puts forward that, as patients 
themselves are willing to spend increased sums on their 
care at the EoL, it may not be that the value of time to the 
individual increases but that the value of alternative uses 
of the individual’s resources decreases.
The Peak End Rule as alternative approach (con). When fol-
lowing the non-linear rationale, periods of time cannot be 
added up at different points in time. Not even after adjust-
ing for quality, since the value behind different time-slices 
may differ.6,12 Normand12 even states that when adding up 
benefits for (different) individuals, theorems in welfare 
economics are violated. This is why it is argued that Kah-
neman et al.’s48 Peak End Rule theory is applicable. The 
idea that there are circumstances where people put more or 
less value on time is supported by this theory. It describes 
that the way people evaluate past experiences tends to be 
based on the most intense points (best or worst) and how 
they end. Authors using Kahnemans’ theory argue that 
people caught in the gravity of approaching death encoun-
ter a profound distortion of how time is experienced and 
valued.29
But … in what direction does it change? (pro). Others, how-
ever, argue that the assumption that time spent in the termi-
nal phase of life is valued more highly is currently without 
empirical support.7 It is stated that even if valuation of time 
changes throughout life, it is not clear in which direction.43 
Furthermore, the valuation of time objection is stated to 
ignore the option of weighing health gains differently for 
different populations.7
Discussion
We integrated theoretical and empirical literature on argu-
ments concerning the appropriateness of using QALYs to 
inform decisions on resource allocation among palliative 
care interventions.20 A total of 13 theoretical and 30 empir-
ical CEAs were included. The theoretical literature encom-
passed studies from various theoretical bases and 
perspectives (Table 4 in Appendix 1), which made the jux-
taposition of all arguments challenging. Nonetheless, three 
themes regarding the pros and cons of using the QALY, as 
well as difficulties concerning its use in research practice 
(CEAs), were identified: (1) life years gained, (2) QoL 
measurement and conceptualization, and (3) valuation and 
additivity of time. Below, we iterate the main arguments 
theme by theme, critically appraise them, and discuss the 
QALY’s value for palliative care and potential implica-
tions for practice or policy.
Theme 1. Life years gained
In this theme, the main argument against the use of the 
QALY is that not enough can be gained in its LY compo-
nent.5,18 This allegedly results in disadvantageous cost-
effectiveness ratios in palliative care compared to other 
healthcare fields.5 Others object that, since the Q weight 
significantly influences the QALY outcome,6,7 increases in 
QALYs are possible even if life is not lengthened. Indeed, 
QALY gains have been reported in empirical studies.27,28
Appraising the above argument, it is clear that—math-
ematically—improvements in QoL can and will generate 
QALYs. However, given the short survival, the scope for 
this (but; also for rises in costs) is clearly limited. Also, 
higher thresholds for diseases with a high disease burden 
can be used. Moreover, we want to emphasize that the dis-
cussion on the appropriateness of using the QALY in CEAs 
in palliative care takes place in the narrow context of eco-
nomic evaluation, where new interventions are compared 
to a “best alternative,” mostly standard care.49 This means 
that in research practice, comparators are faced with the 
same context and constraints. Research has even shown 
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that early palliative care and symptom control not only 
improve QoL but also, without the use of aggressive medi-
cal care, translate into prolonged survival.50–52 So, when 
calculating QALYs in palliative care, there is a fair compe-
tition between competing interventions. Nevertheless, 
when using the QALY for the allocation of financial 
resources on a macro level, other very relevant ques-
tions—such as how much may a QALY cost?53—are in 
play that deserve thorough exploration.
Theme 2. QOL measurement and 
conceptualization
A major perceived objection regarding the use of the 
QALY in palliative care is that it takes into account health-
related domains, which are considered less relevant than 
other dimensions of QoL. Therefore, it is argued that alter-
native QoL measurement instruments should be developed 
that embrace a perspective as broad as the notion of QoL 
itself29 and that the flexibility as offered in the extra-wel-
farist framework even makes it possible to use other QoL 
concepts broader than HR-QoL—such as the capability 
approach.14,31,54 This flexibility, however, is seldom used 
according to some.7,18 Moreover, several authors men-
tioned that standard HR-QoL instruments were used 
because of the assumption that no valuation instrument 
exists that incorporates EoLC issues.
However, to appraise these arguments, there are several 
instruments taking into account EoLC values such as 
peace, emotions, and spiritual and psychosocial well-being 
(e.g. the ICECAP-SCM—measuring capabilities—the 
POS, and the FACIT-Pal).55,56 Probably, they are hardly 
used as they are not suggested in CEA guidelines; the 
EQ-5D is the norm.10,11 But in the QALY framework, devi-
ation from this norm is legitimate with solid arguments. 
Therefore, we recommend researchers in palliative care to, 
in the first place in addition to the EQ-5D, use these alter-
native instruments.
Moreover, a strict weighing of HR-QoL leads to unfa-
vorable QALY results for healthcare domains that do not 
primarily focus on improving HR-QoL (but, for example, 
on improving autonomy, social well-being, or capabili-
ties). In these domains, standard HR measurement tools 
are biased estimators as benefits (other than the EQ-5D 
dimensions) are missed. Therefore, we suggest to move to 
a broader concept of QoL. The time for doing this is right, 
since the new concept of health—in which health no longer 
refers to a state of complete well-being (WHO definition 
1948), but to the ability to adapt and self-manage—more 
or less closes the gap between HR-QoL and QoL.57
Theme 3. Valuation and additivity of time
In the third theme, it is argued that time episodes throughout 
life may be valued differently, and that this should be taken 
into account when making budget allocation decisions. The 
Peak End Rule theory is invoked to back the argument of 
varying valuations of time. To deal with the increasing valu-
ation of time as death gets closer, the PaLY and VIP are 
introduced as alternative approaches. Others pose that it is 
not clear in which direction time preferences act.43
Appraising these arguments, we note that there is no 
scientific consensus on the idea of the increasing valua-
tion, and thus additivity, of time. However, more voices 
are heard on the non-linearity and changing valuation of 
time in proximity to death,48,58 while in the normative 
framework of the QALY, valuation of time is considered 
linear. Other descriptive models on valuation of time—
such as the Peak End Rule,48 maximal endurable time,59 
and lexicographic preferences, for example, the primacy 
of the “Q” over the “LY” weight—may be alternatives. We 
suggest further exploring the possibility of integrating val-
uation of time might be in a non-linear way in the QALY 
framework, for example, by operationalizing the VIP. If it 
is not legitimate to add up quality-adjusted time periods, it 
might be worthwhile to consider “whole experiences” and 
determine how these are valued.48,60
Strengths and limitations
Our integrative review offers the first systematic overview of 
pros and cons for using the QALY to inform decisions on 
resource allocation among palliative care interventions, add-
ing new insights to the broader topical issue of whether eve-
rything that can be done or must be done. In our review, 
however, we focused on “technical” efficiency, informing 
allocation decisions among palliative care interventions only. 
Although this information is of importance, it cannot be used 
to inform on resource allocation throughout healthcare.61 
Moreover, because of controversy about the definition of 
“palliative care” in the field, we might have missed studies of 
importance. Furthermore, since we choose to bundle argu-
ments in pros and cons, and analyzed them from bottom-up, 
our presentation might not have captured every link, making 
the discussion seem more black-and-white than it actually is. 
For example, the link between themes 1 and 3 (if you agree 
that time may not be additive, then the problem of short time 
horizons is less of an issue) was not reflected in the bottom-
up analysis. Finally, although important for the QALY dis-
cussion across the entire width, the debate around QALY 
issues on a macro level, preferences in relation to health, and 
who should value these preferences was put aside.53,62,63
Conclusion
Three themes regarding the appropriateness of using QALYs 
to inform decisions on resource allocation among palliative 
care interventions were identified. The debate as identified 
in theoretical literature is recognized in the empirical litera-
ture. However, alternative outcome measures are not used. 
Despite criticism, concerning theme 1, the limited gain in 
LY in palliative care, QALYs can be gained, despite the fact 
that palliative care itself not primarily aims at this weight. 
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Moreover, in the (narrow) context of economic evaluation, 
new interventions face the same context and constraints as 
their competitors, making the limited-scope issue less of an 
issue. In theme 2, it was argued that standard measurement 
of the Q weight of the QALY—for example, based on the 
EQ-5D or measuring functioning (instead of capabilities) at 
all—does not fit the palliative care context. We recommend 
making use of the possibility to use additional QoL or capa-
bilities measurement instruments that incorporate important 
values for palliative care patients. As for theme 3, we sug-
gest exploring whether valuation of time might be integrated 
into the QALY framework in a non-linear way. In short, the 
QALY might be more valuable when informing decisions 
on resource allocation among palliative care interventions, 
when specific issues related to the above-mentioned themes 
are taken into account.
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Table 6. Main pros and cons of using the QALY in palliative care and suggested alternatives/approaches from theoretical literature 
mapped thematically.
Cons Pros Alternatives
Theme 1 Objective palliative care is to improve QoL, not 
(necessarily) life expectancy.5,18
Fact that “we are all dead in the long run” (Keynes), 
does not make the QALY inapplicable across the 
board.6
 
 QALYs implicit assumption that interventions 
must increase life expectancy flawed.5
Our QoL matters to us while we are alive, and this is 
what the QALY seeks to capture, too.6
 
 Because of low life expectancy, in palliative 
care effects enjoyed over short time, life-saving 
therapy will result in higher QALY gains.5,18
QALY enables comparisons between competing 
demands by combining both quality and quantity of life 
in a single metric.7
 
 Even when costs are modest, palliative 
interventions cannot prove themselves 
cost-effective as no enough time for them to 
generate QALYs.18
Increases in QALYs are possible; even if one of the 
weighing factors does not change significantly (i.e. if 
life cannot be lengthened), improvements can be made 
in the other.7
 
 Developing more accurate QoL instruments 
(link theme 2, red.) would not solve QALY 
problem; limiting factor short life expectancy.6
Other non-life prolonging interventions, only 
increasing QoL (or limiting its potential loss, red.) can 
be measured in QALYs (e.g. hip operations).6,8
 
Theme 2 Analysis of outcomes needs to embrace 
complex and multidimensional objectives of 
palliative care, as broad as notion of QoL 
itself.12,29
Palliative care and QALY are not incompatible. Like 
QALY and cost-utility calculations, palliative care 
involves a benefit-burden analysis.30
Narrative 
theory
 Limitations and standard outcome measures 
(like the EQ-5D) make comparisons 
inappropriate.12
Palliative care can be optimally integrated into the 
calculation of the QALY.8,30
 
 Even if refinement analytical tools lead to 
increased assessment QoL, limiting factor still 
shortens life expectancy.6
QALYs’ ability to rate changes in morbidity and 
mortality in a single measure and to enable comparison 
between competing demands for resources are as 
applicable in this population as in any other.7
 
 Resources tend to be biased away from 
services received at the EoL because they are 
hard to evaluate.12,18
Scoring badly on measure of outcome is not a good 
reason to reject that measure.6
 
 Therapeutic nihilism undermines ability to 
see value beyond cure-oriented disease 
modification.29
If aspects are missed or if there is a lack of precision 
in QALY analysis, this is a shortcoming of ways of 
measuring rather than failing of QALY approach.6,7
 
 Interventions could be assessed based on their 
impact on what a person is able to do or be 
(capabilities) and not solely on functioning.14
In the capability approach, in which capabilities are 
taken into account instead of functioning, QoL is 
measured in a richer evaluative space.14
Capability 
approach
 Dimensions of palliative care that are not 
considered when calculating QALYs can be 
added when using the PalY.12
Instruments could be developed that take account of 
the domains of relevance to a certain population.7
 
 Assumption that there is a mathematical 
continuum between death and excellent health 
is a fundamental problem.5
Non-HR domains can be considered in the QALY, but 
to date, they are not. Fact that researchers have not 
taken advantage of the flexibility (as offered in extra 
welfarism) is not a criticism of the framework itself.7
 
 Bad death can destroy much of value of total 
life,6 allowing a value to be put on components 
of good death.6,12,29,41
Terminal care can be justified in QALY terms when 
refinement of definition of “quality” and “life.”42
 
 Assumption that there is a mathematical 
continuum between death and excellent health 
is a fundamental problem.5
Living with heterogeneity in evidence used for policy 
choices is less serious than fitting all evaluation activity 
into systematically flawed frameworks.18
 
 If EoL patients are treated inequitably, an equity 
weight could be derived and applied as required.7
 
Theme 3 Valuation of time not fixed; it increases as time 
itself is running out.29,30
Relative simplicity: time for any individual at any 
point in time has a constant value, which has useful 
properties (such as being additive).12
Peak End 
Rule
 A value can be put on components of a “good 
death,” which is separate from the days that led 
up to it (PalY).12
Value of time changes throughout life, but not clear in 
which direction variable preference acts.43
PalY
 (Continued)
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Cons Pros Alternatives
 Since valuation of time is not fixed, QALYs’ 
feature of additivity is problematic.5,12
Valuing time spent in terminal phase is more high than 
time during other stages without empirical support.7,43
VIP
 Periods of time cannot be added up at different 
points in time for individuals.12,18
Assumption valuation of time should be determined by 
patients, while accepted practice that values placed on 
health states are determined by general population.43
 
 A QALY gained at the EoL is not equivalent to 
a QALY gained earlier in life.41
It is not clear that palliative patients have greater 
needs than others.6
 
 Way in which life ends impacts overall value of 
that life.42
Objection valuation of time ignores option of weighing 
health gains differently for different populations.7
 
 Benefit EoLC is an addition of value to life as 
whole, independent of any particular time-slice, 
which is not captured by QALY.6
The need-principle cannot be the sole criterion for 
distribution of resources. It should be combined with 
some measure of benefit.6
 
 As time itself is running out, willingness to pay 
for it appears to increase.29
Equity issues arise when resource allocation decisions 
are made based on situations no more unique to 
patients at the EoL than they are at any other life 
stage.7
 
 Economic principles suggest that value of time to 
individuals does not increase, but that value of 
alternative uses of individual resources decreases.43
 
QoL: quality of life; EoL: end of life; QALY: quality-adjusted life year; VIP: Valuation Index Palliative Care; PalY: Palliative Care Yardstick.
Table 6. (Continued)
Table 7. Main pros and cons of using the QALY in palliative care and suggested alternatives/approaches from CEAs mapped 
thematically.
Cons Pros Alternatives
Theme 1 Any survival advantage has a marked effect on the 
cost-effectiveness, which reflects the frequent issue 
that it can be more cost-effective to let patients die 
rather than to use relatively costly treatments.24
The results of this analysis are sensitive 
to changes in costs, but even more so to 
changes in utilities.27
 
 … the results also highlight that palliative care 
interventions are likely to generate high ICERs. This is 
because patients have short remaining life spans over 
which to benefit from any treatment.47
Phippen66 palliative therapies began to gain 
very high QALY values with only modest 
decreases in QoL.
 
 If median survival ⩾18 months, SBRT costs $50,000/
QALY or less, which is commonly cited as a 
benchmark of a ‘good buy’ for medical interventions 
[…] most economically feasible approach would 
involve the judicious use of SBRT for spine metastases 
in patients with relatively long predicted survival.64
With only modest decreases in QoL, both 
selective chemotherapy and single-agent 
chemotherapy with home hospice strategies 
began to exceed ICERs of $100,000/QALY. 
This finding suggests that any survival 
advantage gained in the chemotherapy-
containing treatment arms may be blunted 
by the associated treatment toxicities, 
quickly making them cost-prohibitive.66
 
 These findings illustrate again that survival is by far 
the most important factor to target when striving to 
improve cost-effectiveness in cancer treatment of 
pancreatic carcinoma.25
Survival after palliative therapy is an area 
that demands further research and may 
become a more central issue in palliation 
when treatments are combined.67
 
 If patients survived longer than 6 months, we would 
expect greater cost savings from the intervention.69
 
 The present findings illustrate that prolonged survival 
is a key factor to increasing cost-effectiveness, although 
it becomes necessary to calculate cost-utility over 
limited periods when it is to enable comparisons among 
severely ill patients.25
 
 (Continued)
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Cons Pros Alternatives
Theme 2 Besides these general attributes, there are other 
issues that are also specifically relevant in the 
valuation of EoLC. For example, psychosocial 
outcomes such as relieving the burden of care and 
strengthening relationships with loved ones are not 
included in the EQ-5D. Unfortunately, however, no 
valuation instrument exists that incorporates these 
specific end-of-life issues.38,68
With only modest decreases in QoL, both 
selective chemotherapy and single-agent 
chemotherapy with home hospice strategies 
began to exceed ICERs of $100,000/QALY. 
This finding suggests that any survival 
advantage gained in the chemotherapy-
containing treatment arms may be blunted 
by the associated treatment toxicities, 
quickly making them cost-prohibitive.66
Rehospitalization 
as indicator for 
QoL
 QoL is an important dimension, particularly in 
the palliation of terminal illness. Unfortunately, 
information about the QoL weight (utilities) in 
patients with unresectable pancreatic cancer is 
limited.45
The results of this analysis are sensitive 
to changes in costs, but even more so to 
changes in utilities.27
Utilities on pain, 
since pain is 
the single most 
important factor 
affecting QoL
 Duration of survival is not a meaningful endpoint in 
palliative care […] Chronic pain has enormous effect 
on QoL of patients with bone metastases. Hence, the 
duration of survival, adjusted for the degree of response 
to pain treatment, is a more appropriate endpoint.39
 
 No standardized method available for utility 
collection. […] May be possible QoL item may not 
cover all different domains QoL.27
 
 We observed a high incidence of distressing 
symptoms that may influence the QoL during the 
course of disease and the process of dying.40
 
 The main goals of palliative care and EoLC in brain 
tumor patients are to offer adequate symptom 
control, relief of suffering, avoiding inappropriate 
prolongation of dying, and to support psychological 
and spiritual needs of patients and families. The lack 
of control of symptoms in patients not included 
in palliative home-care programs often lead to 
rehospitalization with an increase in health system 
economic cost and worsening of patient QoL.40
 
Theme 3 Patients were more willing to gamble the risks 
associated with surgery and the possibility of 
developing pain or complications to have an 
opportunity to prolong life than were healthcare 
providers.65
 
 Study takes no account of diminishing marginal utility 
(extra 2 months of good QoL to life-expectancy 
of 6 months potentially more valuable than extra 2 
months to much better average life- expectancy).44
 
 A recent meta-analysis […] suggests that a value 
closer to $100,000/QALY might more accurately 
reflect societal preferences.45
 
 A value closer to $100,000 per QALY might more 
accurately reflect societal preferences.45
 
 Our results indicate that increased expenditures are 
needed to impact patients’ QoL for such morbid 
clinical conditions.47
 
 Patients at the EoL tend to have low QALYs because 
of very poor health status […] this raises the 
question of whether economic evaluations […] ought 
to use some adjustment that would give additional 
weight to gains to health occurring at the EoL.47
 
QALY: quality-adjusted life year; QoL: quality of life; EoL: end of life; EoLC: end-of-life care; ICER: incremental cost-effectiveness ratio; PalY: Pallia-
tive Care Yardstick; EQ-5D: EuroQol Five-Dimensional Questionnaire.
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